Real-World Evidence for GLP-1 Drugs: Special Issue Review
Special issue review compiles real-world evidence for GLP-1 drug use, bridging the gap between clinical trial results and everyday clinical practice outcomes.
Quick Facts
What This Study Found
Special issue review compiles real-world evidence for GLP-1 drug use, bridging the gap between clinical trial results and everyday clinical practice outcomes.
Key Numbers
Specific weight loss percentages not detailed in abstract; results described as surpassing existing approved treatments in earlier phase trials.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Special issue review compiles real-world evidence for GLP-1 drug use, bridging the gap between clini
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.
- Published In:
- Drugs in context, 14 (2025)
- Authors:
- Anderson, Sarah L
- Database ID:
- RPEP-09940
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Special issue review compiles real-world evidence for GLP-1 drug use, bridging the gap between clinical trial results and everyday clinical practice outcomes.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09940APA
Anderson, Sarah L. (2025). Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.. Drugs in context, 14. https://doi.org/10.7573/dic.2025-4-8
MLA
Anderson, Sarah L. "Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.." Drugs in context, 2025. https://doi.org/10.7573/dic.2025-4-8
RethinkPeptides
RethinkPeptides Research Database. "Review: Special Issue: Real-world evidence on the use of GLP..." RPEP-09940. Retrieved from https://rethinkpeptides.com/research/anderson-2025-review-special-issue-realworld
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.